치과용 골이식재 및 골대체재 시장 : 제품 유형, 소재, 제품 형태, 조성, 용도별 - 세계 시장 예측(2026-2032년)

The Dental Bone Grafts & Substitutes Market is projected to grow by USD 2.19 billion at a CAGR of 7.68% by 2032.

Dental bone grafts and substitutes are foundational to implant dentistry, periodontal regeneration, ridge augmentation, sinus lift procedures, and socket preservation. Demand is anchored in verified oral-health burden data: the World Health Organization reports that oral diseases affect around 3.5 billion people globally, while the U.S. CDC reports that nearly half of adults aged 30 years and older have some form of periodontitis, a key driver of alveolar bone loss and grafting needs.

The market is shifting from conventional autografts toward allografts, xenografts, and synthetic bone graft substitutes such as hydroxyapatite, beta-tricalcium phosphate, bioactive glass, and collagen-based matrices. Adoption is reinforced by aging populations, higher dental implant utilization, digital dentistry, and clinician preference for predictable, biocompatible, and workflow-friendly grafting materials with documented safety and performance.

Transformative Shifts Reshaping the Market Landscape

The competitive landscape is being reshaped by minimally invasive implant workflows, guided bone regeneration, chairside digital planning, and biomaterial innovation. Manufacturers are focusing on osteoconductive scaffolds, resorbable membranes, moldable putties, and particulate grafts that support stable space maintenance, defect adaptation, and faster clinical handling.

Regulatory scrutiny is also intensifying. In the United States, dental bone graft materials are typically reviewed through FDA medical device or human tissue frameworks depending on composition and sourcing, while Europe's Medical Device Regulation has increased clinical evidence and post-market surveillance expectations. These shifts favor suppliers with robust quality systems, documented biocompatibility, traceable sourcing, sterile processing controls, and evidence-backed clinical claims.

Cumulative Impact of Artificial Intelligence on Dental Grafting

Artificial intelligence is creating cumulative value across dental bone grafts and substitutes by improving diagnosis, treatment planning, manufacturing quality, and commercial execution. AI-enabled imaging can assist clinicians in assessing bone volume, implant positioning, defect morphology, nerve proximity, and sinus anatomy, supporting more standardized pre-surgical planning when paired with CBCT and digital implant software.

For suppliers, AI can strengthen demand planning, inventory allocation, literature surveillance, complaint analysis, risk management, and regulatory documentation workflows. In R&D, machine learning is increasingly relevant for biomaterial screening, surface characterization, porosity analysis, and formulation optimization, although clinical validation, data governance, cybersecurity, and explainability remain essential for adoption in regulated dental applications.

Key Regional Insights Across Global Dental Grafting Markets

Asia-Pacific is expanding as dental implant awareness rises in China, India, Japan, South Korea, Australia, and ASEAN economies, supported by medical tourism, urban dental chains, digital dentistry adoption, and growing middle-income populations. Japan and South Korea remain technology-forward markets with strong clinician acceptance of guided surgery and advanced biomaterials, while China and India offer large patient pools, increasing private dental investment, and rising demand for implant-supported rehabilitation.

North America continues to be one of the most advanced regions for premium dental bone grafts and substitutes due to high implant penetration, specialist networks, strong private dental spending, accredited training ecosystems, and established FDA-regulated distribution. Europe benefits from mature implant dentistry in Germany, France, Italy, Spain, and the United Kingdom, although Medical Device Regulation compliance is reshaping product portfolios, clinical documentation requirements, and launch timelines.

Latin America is led by Brazil and Mexico, where implant dentistry, dental education, and private-pay procedures are expanding alongside cost-competitive treatment models. The Middle East, especially GCC markets, is supported by premium dental clinics, medical tourism, and demand for esthetic implant dentistry, while Africa remains an emerging opportunity where access, affordability, specialist availability, and cold-chain or sterile logistics vary significantly across countries.

Key Group Insights for Strategic Market Prioritization

ASEAN demand is supported by dental tourism in Thailand, Malaysia, Singapore, Vietnam, and Indonesia, with clinics increasingly adopting guided implant workflows and imported graft materials. The GCC is positioned as a premium care hub, where private hospitals and specialty dental centers prioritize high-quality graft substitutes aligned with implant, esthetic, and full-mouth rehabilitation procedures, while halal compliance and sourcing transparency can influence product acceptance.

The European Union remains a sophisticated but compliance-intensive market under MDR, favoring suppliers with clinical evidence, traceability, vigilance systems, and strong notified-body engagement. BRICS markets present scale advantages through China, India, Brazil, Russia, and South Africa, but pricing pressure, public-private access gaps, domestic manufacturing priorities, and local registration requirements require localized clinical and commercial strategies.

G7 countries continue to shape innovation, evidence generation, and premium product adoption because of advanced dental education, high specialist density, aging populations, and stronger regulatory infrastructure. NATO markets overlap significantly with North America and Europe, creating procurement and compliance environments where supply resilience, cybersecurity, quality assurance, and continuity planning are increasingly important for dental biomaterials suppliers.

Key Country Insights for Dental Bone Grafts & Substitutes

The United States leads in premium implant and regenerative dentistry, supported by specialist periodontal and oral surgery practices, CDC-documented periodontitis prevalence, and strong private dental spending. Canada follows with high clinical standards, established specialist referral networks, and stable demand, while Mexico benefits from cross-border dental tourism, cost-competitive implant procedures, and growing private dental clinic infrastructure.

Brazil is Latin America's key dental innovation and implant market, supported by a large dental workforce, strong domestic demand, and advanced implant training. In Europe, the United Kingdom, Germany, France, Italy, and Spain represent mature markets with significant implant procedure activity, clinician familiarity with guided bone regeneration, and demand for documented biomaterial performance, while Russia remains opportunity-driven but more complex due to geopolitical, currency, regulatory, and supply-chain risks.

China and India provide high-growth potential through large populations, expanding private dental clinics, rising disposable income in urban centers, and increasing awareness of implant-supported restorations. Japan, South Korea, and Australia are advanced Asia-Pacific markets where digital dentistry, quality expectations, aging demographics, and specialist-led treatment planning support adoption of clinically differentiated dental bone graft substitutes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated differentiation rather than commodity positioning. Evidence packages should connect material composition, resorption profile, pore structure, handling properties, membrane compatibility, and outcomes in socket preservation, ridge augmentation, periodontal defects, peri-implant defects, and sinus lift indications.

Companies should also invest in digital dentistry partnerships, AI-enabled planning integrations, clinician education, and procedural training for general dentists and specialists. Regional strategies must account for FDA requirements, EU MDR expectations, tissue sourcing rules, halal considerations in GCC markets, registration complexity in BRICS economies, and price sensitivity in emerging economies.

Research Methodology and Evidence Base

This executive summary is built from secondary research using verified public-health, regulatory, and scientific sources, including WHO oral-health statistics, CDC periodontal disease data, FDA medical device and tissue information, European Medical Device Regulation guidance, OECD health indicators, and peer-reviewed dental implant and biomaterials literature.

The analysis triangulates epidemiology, demographic aging, implant dentistry adoption, regulatory pathways, biomaterial innovation, digital dentistry trends, and regional market dynamics. Insights are interpreted using structured market intelligence practices, emphasizing evidence-backed demand drivers, competitive implications, clinical adoption factors, and actionable strategy for dental bone grafts and substitutes.

Conclusion and Strategic Outlook

The dental bone grafts and substitutes market is advancing from procedure-supportive materials toward evidence-backed regenerative platforms integrated with digital and AI-enabled dentistry. Demand is structurally supported by periodontal disease burden, edentulism, aging populations, trauma-related bone defects, and the global rise of implant-supported rehabilitation.

Organizations that combine biomaterial performance, regulatory excellence, clinical education, ethical sourcing, supply reliability, and region-specific commercialization will be best positioned to compete. The strongest opportunities will emerge where innovation meets affordability, documentation, and predictable clinical outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Dental Bone Grafts & Substitutes Market, by Product Type

• 7.1. Allografts
  • 7.1.1. Demineralized Freeze Dried Bone Allograft (DFDBA)
  • 7.1.2. Freeze Dried Bone Allograft (FDBA)
• 7.2. Autografts
• 7.3. Composite Grafts
  • 7.3.1. Ceramic Composites
  • 7.3.2. Organic Composites
• 7.4. Synthetic Grafts
  • 7.4.1. Bioactive Glass
  • 7.4.2. Ceramics
  • 7.4.3. Polymers
• 7.5. Xenografts
  • 7.5.1. Bovine
  • 7.5.2. Porcine

8. Dental Bone Grafts & Substitutes Market, by Material

• 8.1. Bioactive Glass
• 8.2. Calcium Sulfate
• 8.3. Composite Materials
• 8.4. Hydroxyapatite
• 8.5. Tricalcium Phosphate

9. Dental Bone Grafts & Substitutes Market, by Product Form

• 9.1. Granules
• 9.2. Putty
• 9.3. Blocks
• 9.4. Injectable

10. Dental Bone Grafts & Substitutes Market, by Composition

• 10.1. Single Material
• 10.2. Composite Materials

11. Dental Bone Grafts & Substitutes Market, by Application

• 11.1. Implant Bone Regeneration
• 11.2. Ridge Augmentation
• 11.3. Sinus Lift
• 11.4. Socket Preservation
• 11.5. Periodontal Defect Regeneration

12. Dental Bone Grafts & Substitutes Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Dental Bone Grafts & Substitutes Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Dental Bone Grafts & Substitutes Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. BioHorizons Implant Systems, Inc.
• 16.2. Biomatlante SAS
• 16.3. botiss biomaterials GmbH
• 16.4. Dentium Co., Ltd.
• 16.5. Dentsply Sirona Inc.
• 16.6. Envista Holdings Corporation
• 16.7. Geistlich Pharma AG
• 16.8. Institut Straumann AG
• 16.9. Johnson & Johnson Services, Inc.
• 16.10. Kuros Biosciences AG
• 16.11. LifeNet Health, Inc.
• 16.12. Medtronic plc
• 16.13. MegaGen Implant Co., Ltd.
• 16.14. NovaBone Products, LLC
• 16.15. Osteogenics Biomedical, Inc.
• 16.16. Purgo Biologics Co., Ltd.
• 16.17. RTI Surgical Holdings, Inc.
• 16.18. Salvin Dental Specialties, Inc.
• 16.19. Stryker Corporation
• 16.20. Sunstar Suisse S.A.
• 16.21. Zimmer Biomet Holdings, Inc.
• 16.22. ZimVie Inc.